Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous ICH and Established, or Risk Factors for, Atherosclerosis

NCT05159219 is registered in ClinicalTrials.gov with Population Health Research Institute as lead sponsor.

NCT NCT05159219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous ICH and Established, or Risk Factors for, Atherosclerosis
Lead sponsor
Population Health Research Institute
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2022
Completion date
December 3, 2024
Enrollment
100 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial hemorrhages